Physician profile
Lorraine Myers Provencher
NPI 1174935910
$220,182.11
in general payments reported to CMS, 2019-2025
29 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $315 · 2021: $12K · 2022: $7,279 · 2023: $59K · 2024: $77K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $148K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Honoraria: $6,928 · Food and Beverage: $6,751 · Travel and Lodging: $3,712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $147,602.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,425.00 |
| Honoraria | $6,927.78 |
| Food and Beverage | $6,751.13 |
| Travel and Lodging | $3,712.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $73,485.75 | 2022-2025 | |
| Alcon Vision LLC | $51,281.74 | 2022-2025 | Hydrus Microstent, Voyager Dslt, Systane |
| Microsurgical Technology, INC. | $28,250.00 | 2023-2024 | |
| Glaukos Corporation | $27,831.45 | 2022-2025 | Idose, Travoprost Intraocular Implant - Idose, Photrexa Viscous and Photrexa |
| Allergan, INC. | $10,306.07 | 2019-2022 | |
| Alcon Research LLC | $10,247.85 | 2023-2025 | Rocklatan |
| New World Medical,INC. | $7,631.54 | 2022-2025 | Clearpath, Streamline, Kahook Dual Blade |
| Thea Pharma INC. | $3,037.50 | 2023 | Iyuzeh |
| Ivantis, INC | $2,955.39 | 2021 | |
| Rxsight INC | $2,374.75 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Bausch & Lomb Americas INC. | $1,810.55 | 2022-2025 | Xiidra, Vyzulta |
| Harrow Eye, LLC | $212.41 | 2025 | |
| Aerie Pharmaceuticals, INC. | $147.01 | 2019-2021 | |
| Ocular Therapeutix, INC. | $142.11 | 2023 | Dextenza |
| Tarsus Pharmaceuticals, INC. | $126.99 | 2024-2025 | Xdemvy |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $46.49 | 2023 | Syfovre |
| Oyster Point Pharma, INC. | $37.08 | 2024 | Tyrvaya, Ryzumvi |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.82 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $31.20 | 2023 | Tecnis Simplicity |
| Regeneron Healthcare Solutions, INC. | $30.50 | 2023 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $30.32 | 2022-2023 | |
| Biotissue Holdings INC. | $24.46 | 2024 | |
| Rayner Intraocular Lenses Limited | $21.54 | 2025 | Omidria |
| Dompe US, INC. | $19.68 | 2025 | Oxervate |
| Amgen INC. | $18.47 | 2025 | Tepezza |
| Alimera Sciences, INC. | $18.07 | 2022 | |
| Sun Pharmaceutical Industries INC. | $17.65 | 2023 | Cequa |
| Eyevance Pharmaceuticals LLC | $12.72 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorraine Provencher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.